Bristol-Myers Squibb (BMY) CheckMate -459 Study Evaluating Opdivo as First-Line Treatment for Patients with Unresectable HCC Did Not Meet Primary Endpoint
June 24, 2019 7:00 AM
Bristol-Myers Squibb Company (NYSE: BMY) today announced topline results from CheckMate -459, a randomized Phase 3 study evaluating Opdivo (nivolumab) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
